SOURCE: BioElectronics Corporation

BioElectronics Corporation

August 15, 2011 09:30 ET

BioElectronics Introduces Smart Insole™ With Patented Therapy Into the Billion Dollar+ Worldwide Foot Care Market

FREDERICK, MD--(Marketwire - Aug 15, 2011) - BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free topical pain devices is pleased to announce a major advancement in heel pain therapy through its introduction of a ground-breaking new product called, Smart Insole™. This new unique product is a comfortable gel insole embedded with the Company's patented, clinically proven pain therapy for the millions of runners and standing foot weary workers. The Wall Street Journal has recognized the device as one of the top medical innovations of 2009.

"We believe this product holds the promise to radically change the market dynamics within the billion dollar plus foot care market," commented Hudson Levy, ActiPatch Brand Manager of BioElectronics. "This gel insole product, which has been under development for more than two years, is like no other product on the market today. We have been able to miniaturize our core technology into a form factor that can easily be contained and replaced within a high-performance gel insert. The result is a product the consumers can simply slide into their shoes for daytime wear and into an easy to wear night slipper for 24/7 continuous healing therapy from our time tested and clinically proven advanced pain therapy. Currently there is neither comparative therapy nor competitive products on the market."

A clinical study involving 70 patients suffering from heel pain confirmed that those wearing this therapy overnight experienced progressively less pain each morning. By embedding the device into a gel insole, users can now experience added relief throughout the day as well the proven nighttime therapy to accelerate pain relief and healing.

It has been estimated that one million physician visits per year in the United States are for the diagnosis and treatment of foot and heel pain. As the population ages and weights increase, the rates of foot-related pain and plantar fasciitis are dramatically accelerating creating an unprecedented demand for pain relief products to treat these conditions.

Mr. Levy continued, "Based on our recent conversations with major retailers in both the United States and abroad, it is clear that the foot care sector continues to grow strongly. While this is very encouraging, we are even more excited that retailers continue to express great interest in new foot care products since there have been few therapeutic innovations. We believe our new Smart Insole and future foot care products are what retailers and their customers have been waiting for."

About BioElectronics Corporation

BioElectronics Corporation is an award winning medical device developer and manufacturer of advanced pain therapy medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see


This press release contains certain statements that may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events or developments that we intend, expect, plan, project, believe or anticipate will or may occur in the future are forward-looking statements. Forward-looking statements are based on certain assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions and expected future developments. Actual results and the timing of events may differ materially from those contemplated by the forward-looking statements due to a number of factors. BioElectronics refers you to the cautionary statements and risk factors set forth in the documents it has filed with the Securities and Exchange Commission. The company is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information

  • Contact:
    Ben Fichter
    BioElectronics, Inc.
    (301) 874-4890